

Other; specify \_\_\_

☐ Immunodeficiency-associated lymphoproliferative disorder (incl. PTLD)

EBMT	EBMT Centre Identification Code (CIC): Hospital Unique Patient Number (UPN): Patient Number in EBMT Registry:	Treatment Type
	LYMPH	OMAS
	DISEA	ASE
	te this form only if this diagnosis was the indication.	tion for the HCT/CT or if it was specifically requested.
Date of diagn	osis: / / (YYYY/MM/DD)	
Classification	ı:	
☐ B-cell lym	phoma (including Hodgkin and Non-Hodgkin lympho	oma)
☐ T-cell non	-Hodgkin lymphoma (NHL)	

Lymphomas\_v2.2 1 of 10 2025-03-19



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST ☐ Other
Hospital Unique Patient Number (UPN):			
Patient Number in EBMT Registry:	Treatment Date _	//YY	YY/MM/DD)

# LYMPHOMAS B-cell lymphoma (including Hodkin and Non-Hodkin lymphoma)

DISEASE
Sub-Classification: Mature B-cell neoplasms
Splenic B-cell lymphomas and leukaemias
Splenic marginal zone lymphoma
Splenic diffuse red pulp small B-cell lymphoma
Lymphoplasmacytic lymphoma
☐ IgM-LPL/ Waldenström Macroglobulinaemia (WM) type
☐ Non-WM type LPL
☐ Marginal zone lymphoma
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
☐ Primary cutaneous marginal zone lymphoma
☐ Nodal marginal zone lymphoma
☐ Paediatric marginal zone lymphoma
Follicular lymphoma
☐ Classical follicular lymphoma (cFL)
FL with uncommon features (uFL)
Decidiatria tuna falliaular humphama
Paediatric-type follicular lymphoma
Duodenal-type follicular lymphoma
Cutaneous follicle centre lymphoma
Mantle cell lymphoma
☐ Mantle cell lymphoma
Leukaemic non-nodal mantle cell lymphoma



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT Registry:	Treatment Date _	//(YY	YY/MM/DI	D)

### LYMPHOMAS B-cell lymphoma (including Hodkin and Non-Hodkin lymphoma)

### DISEASE continued

Sub-Classification: Mature B-cell neoplasms
☐ Large B-cell lymphomas
☐ Diffuse large B-cell lymphoma (DLBCL), NOS
☐ Germinal centre B- cell-like subtype (GCB)
☐ Activated B-cell-like subtype (ABC)
☐ T-cell/histiocyte-rich large B-cell lymphoma
☐ Diffuse large B-cell lymphoma/ high grade B-cell lymphoma with MYC and BCL2 rearrangements
☐ ALK-positive large B-cell lymphoma
☐ Large B-cell lymphoma with IRF4 rearrangement
☐ High-grade B-cell lymphoma with 11q aberrations
☐ Lymphomatoid granulomatosis
☐ EBV-positive diffuse large B-cell lymphoma
☐ Diffuse large B-cell lymphoma associated with chronic inflammation
☐ Fibrin-associated large B-cell lymphoma
☐ Fluid overload-associated large B-cell lymphoma
Plasmablastic lymphoma
Primary large B-cell lymphoma of immune-privileged sites
Primary large B-cell lymphoma of the CNS
Primary large B-cell lymphoma of the vitreoretina
Primary large B-cell lymphoma of the testis
Primary cutaneous diffuse large B-cell lymphoma, leg type
☐ Intravascular large B-cell lymphoma
Primary mediastinal large B-cell lymphoma
☐ Mediastinal grey zone lymphoma
☐ High-grade B-cell lymphoma, NOS
☐ Burkitt lymphoma
☐ EBV-positive BL
☐ EBV-negative BL
☐ KSHV/HHV8-associated B-cell lymphoid proliferations and lymphomas
Primary effusion lymphoma
☐ KSHV/HHV8-positive diffuse large B-cell lymphoma
☐ KSHV/HHV8-positive germinotropic lymphoproliferative disorder
☐ Hodgkin lymphoma
☐ Classic Hodgkin lymphoma
☐ Nodular lymphocyte predominant Hodgkin lymphoma



☐ Not evaluated

EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT Registry:	Treatment Date	//YY	YY/MM/DI	D)

DISEASE continued							
Transformation of indolent B-cell lymphoma:  No Yes (If not reported yet, complete respective non-indication diagnosis form in addition to the current form) Unknown							
Parameters for internation	Parameters for international prognostic indices:						
Age at diagnosis:	years (	this is calculated automatic	ally in the database)				
LDH levels elevated:	☐ No ☐ Yes	☐ Not evaluated ☐	Unknown				
Ann Arbor staging:	_	□ III □ IV	☐ Not evaluated ☐ Unknown				
ECOG performance state	us: 🔲 0 🔲 1	2 3 4	☐ Not evaluated ☐ Unknown				
> 1 extranodal site involv	ved: No Yes	☐ Not evaluated ☐	Unknown				
> 4 nodal sites involved:	□ No □ Yes	☐ Not evaluated ☐	Unknown				
Haemoglobin < 120g/L:	□ No □ Yes	☐ Not evaluated ☐	Unknown				
White Blood Cell count:	x 10 <sup>9</sup> /L	☐ Not evaluated ☐	Unknown				
CNS Involvement:	☐ No ☐ Yes	☐ Not evaluated ☐	Unknown				
Follicular lymphoma, Wald	enstrom macroglobulinaemia	a) ·	vileged sites), Mantle cell lymphoma,				
IPI: (for LBCL (except Primary large B-cell lymphoma of immune-privileged sites) and FLBL)	MIPI: (for Mantle cell lymphoma)	<b>FLIPI:</b> (for Follicular lymphoma (except FLBL))	ISSWM: (for Waldenstrom macroglobulinaemia)				
Low risk (0-1 score points)	☐ Low risk	Low risk	Low risk (0-1 score points except age > 65)				
Low-intermediate risk (2 score points)	☐ Intermediate risk☐ High risk	☐ Intermediate risk☐ High risk	Intermediate risk (2 score points OR age > 65)				
High-intermediate risk (3 score points)  High risk (4-5 score points)	☐ Not evaluated	☐ Not evaluated	☐ High risk (3-5 score points) ☐ Not evaluated				

Lymphomas\_v2.2 4 of 10 2025-03-19



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT Registry:	Treatment Date	//YY	YY/MM/DI	D)

#### **CHROMOSOME ANALYSIS**

Please complete chromosome analysis section only for patients with the following types of B-cell NHL:

- Mantle cell lymphoma (including Leukaemic non-nodal mantle cell lymphoma) & for Waldenström Macroglobulinaemia (IgM-LPL/ Waldenström Macroglobulinaemia (WM) in new classification)

<ul> <li>Burkitt lymphoma (including EBV-positive BL &amp; EBV-negative BL) &amp; for all LBCL</li> <li>For all B-cell lymphoma,</li> </ul>						
(Describe results of the	done before HCT/CT treatment: most recent complete analysis) tput of analysis:   Separate abr	normalities 🔲 Fu	ll karyotype			
If chromosome analy What were the resu  Normal Abnormal: numbe						
Date of chromosom	e analysis:: / / (YYY	<i>Y/MM/DD)</i> ☐ Unkr	own			
For abnormal results, in lymphoma diagnosed).	dicate below whether the abnormalit	ties were absent, pres	sent or not ev	aluated <i>(acco</i>	rding to the type of	
Mantle cell lymphoma	del(17p)		Absent	Present	☐ Not evaluated	
or Waldenstrom macro- globulinaemia		FISH used:	☐ No	☐ Yes		
	t(2;8)		Absent	Present	☐ Not evaluated	
Burkitt lymphoma or all	t(8;14)		Absent	Present	☐ Not evaluated	
LBCL	t(8;22)		☐ Absent	Present	☐ Not evaluated	
	t(14;18)		Absent	Present	☐ Not evaluated	
All above mentioned B-cell lymphomas	Other chromosome abnormalities	s; specify:	Absent	Present		
Transcribe the comple	te karyotype:	OR				

<b>EBMT</b> Hospita	Centre Identification Code (CIC): I Unique Patient Number (UPN): Number in EBMT Registry:	Treatment Type
	MOLECULAR MARKER	ANALYSIS
<ul> <li>Mantle cell lymphoma</li> <li>Burkitt lymphoma (inclied All LBCL are BCL2 reares)</li> <li>For all B-cell lymphomas</li> <li>Molecular marker and</li> </ul>	cular marker analysis section only for patients with (including Leukaemic non-nodal mantle cell lymphoma) uding EBV-positive BL & EBV-negative BL) trangement & BCL6 rearrangement allysis done before HCT/CT treatment: e most recent complete analysis)	h the following types of B-cell NHL:
Date of molecular ma	arker analysis (if tested):: / / (YYY	Y/MM/DD)
Indicate below whethe	r the markers were absent, present or not evaluat	ed, according to the type of lymphoma diagnosed.
Mantle cell lymphoma	TP53 mutation	☐ Absent ☐ Present ☐ Not evaluated
Burkitt lymphoma or al LBCL	MYC rearrangement	☐ Absent ☐ Present ☐ Not evaluated
All LBCL	BCL2 rearrangement	☐ Absent ☐ Present ☐ Not evaluated
All EBCE	BCL6 rearrangement	☐ Absent ☐ Present ☐ Not evaluated
All above mentioned B-cell lymphomas	Other molecular markers; specify:	Absent Present
	IMMUNOPHENOTY	PING
	nunophenotyping section only for patients with the a (including <b>Leukaemic non-nodal mantle cell lymphoma</b>	
	cluding EBV-positive BL & EBV-negative BL)	,
• All LBCL		
• For all B-cell lymphoma	as	
	g done before HCT/CT treatment: ne most recent complete analysis)	
_	notyping (if tested): / / ( <i>YYYY/MM</i>	//DD)
		r not evaluated, according to the type of lymphoma
Mantle cell lymphoma	SOX 11	☐ Absent ☐ Present ☐ Not evaluated
Burkitt lymphoma or all LBCL	мус	☐ Absent ☐ Present ☐ Not evaluated
PCI.	BCL2/lgH	☐ Absent ☐ Present ☐ Not evaluated
_BCL _	BCL6	□ Absent □ Present □ Not evaluated

Lymphomas\_v2.2 6 of 10 2025-03-19

☐ Absent ☐ Present

Other immunophenotype; specify: \_

All above mentioned

B-cell lymphomas



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT Registry:	Treatment Date _	//(YY	YY/MM/DI	D)

LYMPHOMAS	
T-cell non-Hodgkin lymphoma	(NHL)

DISEASE		
Sub-Classification: Mature T-cell & NK-cell neoplasms		
☐ Mature T-cell and NK-cell leukaemias		
☐ T-large granular lymphocytic leukaemia		
☐ NK-large granular lymphocytic leukaemia		
☐ Adult T-cell leukaemia/lymphoma		
☐ Sezary syndrome		
☐ Aggressive NK-cell leukaemia		
☐ Primary cutaneous T-cell lymphomas		
☐ Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder		
☐ Primary cutaneous acral CD8-positive lymphoproliferative disorder		
☐ Mycosis fungoides		
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: lymphomatoid papulosis		
Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma		
☐ Subcutaneous panniculitis-like T-cell lymphoma		
☐ Primary cutaneous gamma/delta T-cell lymphoma		
☐ Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma		
Primary cutaneous peripheral T-cell lymphoma, not otherwise specified		
☐ Intestinal T-cell and NK-cell lymphoid proliferations and lymphomas		
☐ Indolent T-cell lymphoma of the gastrointestinal tract		
$\square$ Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract		
☐ Enteropathy-associated T-cell lymphoma		
☐ Monomorphic epitheliotropic intestinal T-cell lymphoma		
☐ Intestinal T-cell lymphoma not otherwise specified		
☐ Hepatosplenic T-cell lymphoma		
☐ Anaplastic large cell lymphomas		
ALK-positive anaplastic large cell lymphoma		
☐ ALK-negative anaplastic large cell lymphoma		
☐ Breast implant-associated anaplastic large cell lymphoma		



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT Registry:	Treatment Date _	//YY	YY/MM/DI	D)

## LYMPHOMAS T-cell non-Hodgkin lymphoma (NHL)

DISEASE continued
Sub-Classification: Mature T-cell & NK-cell Neoplasms
☐ Nodal T-follicular helper (TFH) lymphomas
☐ Nodal TFH cell lymphoma, angioimmunoblastic-type
☐ Nodal TFH cell lymphoma, follicular type
☐ Nodal TFH cell lymphoma, not otherwise specified
Peripheral T-cell lymphoma, not otherwise specified
☐ EBV-positive NK/T-cell lymphomas
☐ EBV-positive nodal T- and NK-cell lymphoma
☐ Extranodal NK/T-cell lymphoma
☐ EBV-positive T- and NK-cell lymphoid proliferations and lymphomas of childhood
Severe mosquito bite allergy
☐ Hydroa vacciniforme lymphoproliferative disorder
Systemic chronic active EBV disease
Systemic EBV-positive T-cell lymphoma of childhood



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT Registry:	Treatment Date _	//(YY	YY/MM/DI	D)

### LYMPHOMAS

Immunodeficiency-associated lymphoproliferative disorders (incl. PTLD)
DISEASE
Sub-Classification: Immunodeficiency-associated lymphoproliferative disorders (incl. PTLD)
Lymphoproliferative disease associated with primary immune disorder
Lymphoma associated with HIV infection
Post-transplant lymphoproliferative disorder (PTLD)
☐ Non-destructive PTLD
☐ Plasmacytic hyperplasia PTLD
☐ Infectious mononucleosis PTLD
☐ Florid follicular hyperplasia PTLD
☐ Polymorphic PTLD
☐ Monomorphic PTLD
☐ B-cell type
☐ T-/NK-cell type
☐ Classical Hodgkin lymphoma PTLD
Other immunodeficiency-associated lymphoproliferative disorder
Did the disease result from a previous solid organ transplant?  □ No
Yes: Date of transplant:/ (YYYY/MM/DD)
Type of transplant: Renal
☐ Cardiac
☐ Pulmonary
Other; specify:
☐ Unknown

Lymphomas\_v2.2 9 of 10 2025-03-19



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT Registry:	Treatment Date	//YY	YY/MM/DI	D)

LYMPHOMA
----------

	PREVIOUS THERAPIES (between diagnosis and HCT/C	PREVIOUS THERAPIES (between diagnosis and HCT/CT)		
Previous	therapy lines before the HCT/CT:			
☐ No				
☐ Yes:	complete the "Treatment — non-HCT/CT/GT/IST" form			
☐ Unkn	nown			